A new lead against resistant bacteria.
Scientists identified abaucin, a compound active against Acinetobacter baumannii, with help from deep learning.
- Maturity
- Experimental, stage 1 of 4
- Support
- 1 source · paper
- Evidence detail
- How we know ↓
Antibiotic resistance narrows the options for treating infections.
Screening compounds experimentally is resource intensive.
A model prioritized compounds for laboratory testing.
What was shown, and what wasn’t
Shown
Abaucin showed activity in experiments, including a mouse wound infection model.
Not shown · limits
- Preclinical evidence. Human safety and efficacy are not established.
Bright editorial interpretation
A possible starting point for developing a narrow-spectrum antibiotic.
Still open
Investigate mechanism, optimize the compound, and assess safety before clinical translation.
How we know1 source · checked 2026-09-05 · no corrections
Original sources
Institutions: McMaster University & MIT
- Maturity
- Experimental
- Source published
- 2023-05-25
- Last source review
- 2026-09-05
- Editorial method
- Original source check
- Place / relevance
- Hamilton, Canada · institution-location
Bright compared this account with the linked original and supporting sources and kept reported, budgeted, projected, and observed claims distinct. Bright did not independently audit the underlying records.
Maturity describes the tested or operational setting. Confidence describes support for the particular claim; one does not determine the other.
Revision & correction history
No corrections recorded.
Keep exploring
Explore the shared question in another setting. These connections do not imply replication.